Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 22.64% | 25.50% | -83.46% | -83.87% | 1,396.08% |
| Total Depreciation and Amortization | 0.00% | 2.78% | 80.00% | 71.43% | 80.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 134.09% | 139.56% | -271.25% | -266.98% | 108.45% |
| Change in Net Operating Assets | -599.45% | -611.12% | -654.30% | -635.74% | 8,755.83% |
| Cash from Operations | -93.38% | -93.23% | -145.14% | -144.03% | 1,374.00% |
| Capital Expenditure | 68.06% | 68.06% | 83.33% | 83.87% | -140.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 102.01% | 102.06% | 101.76% | 101.72% | -- |
| Cash from Investing | 102.01% | 102.05% | 101.75% | 101.71% | -1,783,203.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | 50.36% | 50.36% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -28.57% | -28.57% | -- |
| Cash from Financing | -513.36% | -523.02% | 48.47% | 44.81% | -- |
| Foreign Exchange rate Adjustments | -589.55% | -600.96% | 852.11% | 833.44% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.73% | 102.80% | -699.93% | -680.17% | -332.09% |